tiprankstipranks
Trending News
More News >
Voyager Therapeutics (VYGR)
NASDAQ:VYGR

Voyager Therapeutics (VYGR) AI Stock Analysis

Compare
1,123 Followers

Top Page

VY

Voyager Therapeutics

(NASDAQ:VYGR)

Rating:42Neutral
Price Target:
$3.00
▼(-1.32%Downside)
Voyager Therapeutics faces significant financial and valuation challenges. Declining revenues and negative profitability measures weigh heavily on its financial performance. Technical analysis provides mixed signals, with bearish momentum from moving averages. The absence of a dividend yield and a negative P/E ratio further impact the valuation score negatively.
Positive Factors
Financial Position
Voyager has $295M in cash and a projected runway into mid-2027, indicating meaningful potential value creation from clinical advancement, partnering activity, and platform validation.
Market Valuation
Analyst views VYGR as undervalued ahead of upcoming catalysts.
Partnership Milestones
VYGR could realize up to $35mm in regulatory and clinical milestones related to the FXN/GBA1 programs.
Negative Factors
Earnings Performance
Net loss per share was ($0.53) vs consensus of ($0.45).
Market Sentiment
The stock has pulled back approximately 43% this year due to macro factors and investor apathy around small/mid-cap biotech.
Stock Price Target
The price target has been reduced from $13 to $12.

Voyager Therapeutics (VYGR) vs. SPDR S&P 500 ETF (SPY)

Voyager Therapeutics Business Overview & Revenue Model

Company DescriptionVoyager Therapeutics, Inc. (VYGR) is a biotechnology company focused on developing life-changing gene therapies for patients suffering from severe neurological diseases. The company's core offerings include a pipeline of innovative products targeting conditions such as Parkinson's disease, Huntington's disease, and other rare, debilitating neurological disorders. By leveraging its proprietary adeno-associated virus (AAV) vector platform, Voyager aims to deliver gene therapies that address the underlying genetic causes of these diseases, providing potential long-term therapeutic benefits.
How the Company Makes MoneyVoyager Therapeutics makes money primarily through strategic collaborations, licensing agreements, and milestone payments related to its gene therapy programs. The company partners with larger pharmaceutical firms to co-develop and commercialize its therapeutic candidates, which enables it to share in the research and development costs while also receiving upfront payment, milestone payments, and potential royalties on sales. Additionally, Voyager may receive government grants or other funding to support its research initiatives. These partnerships and funding sources are critical to advancing its pipeline and generating revenue before its therapies reach commercialization.

Voyager Therapeutics Earnings Call Summary

Earnings Call Date:May 06, 2025
(Q4-2024)
|
% Change Since: -6.46%|
Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment Positive
The earnings call presented a positive outlook with significant advancements and strong financial positioning. Despite a setback in the SOD1 silencing program, the progress in tau-targeting therapies and potential substantial milestone payments from partnerships highlight a promising future.
Q4-2024 Updates
Positive Updates
Strong Cash Position and Potential Milestone Payments
Voyager Therapeutics reported $332 million in cash as of the end of 2024, with potential future milestone payments totaling $8.2 billion from partnerships.
Advancements in Tau Silencing Program
The tau silencing gene therapy program, VY1706, moved forward into IND-enabling studies, showing 50% to 73% knockdown of tau messenger RNA in non-human primate studies.
Positive Results for Anti-Tau Antibody VY7523
VY7523 performed well in a single ascending dose study with no serious adverse events, showing dose-proportional pharmacokinetics and a CSF to serum ratio of 0.3%.
Promising External Data Supporting Anti-Tau Strategies
UCB's bepranemab demonstrated impact on tau accumulation, and further data from Merck and other companies are anticipated, which may support the potential of tau-targeted therapies.
Progress in Partnered Programs with Neurocrine
Two programs with Neurocrine are expected to enter the clinic or have an IND filed this year, indicating positive collaboration progress.
Negative Updates
Setback in SOD1 Silencing Gene Therapy Program
The SOD1 silencing gene therapy program moved back into the research stage due to the payload not meeting the target profile, requiring the identification of a new payload.
Challenges in Establishing Capsid Proof of Concept
The company is looking to establish capsid proof of concept through upcoming programs with Neurocrine, following complications with the SOD1 program.
Company Guidance
During the Voyager Therapeutics Fourth Quarter and Year-End 2024 Financial Results Conference Call, the company provided several key metrics and updates about their progress and future plans. Voyager reported $332 million in cash as of the end of 2024 and highlighted potential future milestone payments totaling $8.2 billion, emphasizing the significance of their partnerships as a source of non-dilutive revenue. The company is advancing its tau silencing gene therapy, VY1706, into IND-enabling studies, targeting IND submission in 2026, with promising non-human primate study results showing 50% to 73% knockdown of tau messenger RNA across the brain. Additionally, the anti-tau antibody, VY7523, showed favorable results in a single ascending dose study, with a CSF to serum ratio of 0.3%. Voyager expects initial tau PET data from a multiple ascending dose study in Alzheimer's patients in the second half of 2026. They also noted their $2.9 billion in developmental milestones and guidance extending their cash runway to mid-2027.

Voyager Therapeutics Financial Statement Overview

Summary
Voyager Therapeutics faces significant financial challenges, including revenue volatility, negative profit margins, and strained cash flow. Despite a stable equity position and manageable leverage, the company's profitability and cash flow sustainability are major concerns.
Income Statement
34
Negative
Voyager Therapeutics has experienced significant revenue volatility, with recent declines from previous highs, reflecting potential challenges in maintaining consistent revenue streams. The TTM Gross Profit Margin is 48.54%, indicating some efficiency in managing production costs, but the Net Profit Margin is negative, highlighting ongoing profitability challenges. The EBIT and EBITDA Margins are also negative, reinforcing the company's struggles to achieve operational profitability.
Balance Sheet
58
Neutral
The company's balance sheet shows a relatively stable equity position with a Debt-to-Equity Ratio of 0.15, suggesting manageable leverage levels. The Equity Ratio is robust, at 77.20%, indicating strong equity financing. However, Return on Equity is negative due to persistent net losses, which is a concern for investors seeking returns.
Cash Flow
42
Neutral
The company's cash flow situation is strained, with negative Free Cash Flow growth, indicating challenges in generating cash from operations. The Operating Cash Flow to Net Income Ratio is negative, reflecting difficulties in converting income into cash flow. Despite these challenges, there was a significant cash inflow from financing activities in the prior period, which temporarily bolstered liquidity.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue66.96M80.00M250.01M40.91M37.41M171.13M
Gross Profit32.51M80.00M245.57M34.72M-36.37M62.38M
EBITDA-97.25M-78.56M126.45M-44.65M-68.45M31.20M
Net Income-84.69M-65.00M132.33M-46.41M-66.03M36.74M
Balance Sheet
Total Assets353.24M393.05M351.28M159.36M193.85M261.58M
Cash, Cash Equivalents and Short-Term Investments236.02M266.68M230.88M118.85M132.54M181.14M
Total Debt42.00M43.73M20.29M23.13M44.18M47.61M
Total Liabilities80.54M93.29M114.96M100.34M98.80M107.26M
Stockholders Equity272.70M299.76M236.32M59.02M95.06M154.32M
Cash Flow
Free Cash Flow-114.01M-18.83M74.66M-15.00M-55.13M-108.81M
Operating Cash Flow-111.97M-15.31M77.92M-12.51M-53.52M-96.72M
Investing Cash Flow42.41M-94.86M-141.64M-7.34M65.91M113.00M
Financing Cash Flow1.24M114.02M33.65M1.11M612.00K3.16M

Voyager Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price3.04
Price Trends
50DMA
3.23
Negative
100DMA
3.50
Negative
200DMA
4.83
Negative
Market Momentum
MACD
-0.04
Negative
RSI
45.55
Neutral
STOCH
52.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VYGR, the sentiment is Negative. The current price of 3.04 is below the 20-day moving average (MA) of 3.18, below the 50-day MA of 3.23, and below the 200-day MA of 4.83, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 45.55 is Neutral, neither overbought nor oversold. The STOCH value of 52.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VYGR.

Voyager Therapeutics Risk Analysis

Voyager Therapeutics disclosed 72 risk factors in its most recent earnings report. Voyager Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Voyager Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (59)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
59
Neutral
HK$15.37B5.69-7.44%4.08%11.55%-28.15%
50
Neutral
$285.95M322.49%-30.66%36.48%
50
Neutral
$285.95M322.49%-30.66%36.48%
47
Neutral
$196.42M-32.97%
47
Neutral
$196.42M-32.97%
45
Neutral
$349.35M-32.12%10.98%
43
Neutral
$408.33M-115.21%20.58%
42
Neutral
$168.22M5.05-27.61%-43.75%-8479.41%
38
Underperform
$299.52M-66.13%43.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VYGR
Voyager Therapeutics
3.04
-4.94
-61.90%
ANNX
Annexon Biosciences
2.73
-2.32
-45.94%
FHTX
Foghorn Therapeutics
4.78
-0.10
-2.05%
FHTX
Foghorn Therapeutics
4.78
-0.10
-2.05%
FDMT
4D Molecular Therapeutics
3.95
-18.74
-82.59%
FDMT
4D Molecular Therapeutics
3.95
-18.74
-82.59%
TERN
Terns Pharmaceuticals
4.00
-3.45
-46.31%
PRME
Prime Medicine, Inc.
3.80
-1.82
-32.38%

Voyager Therapeutics Corporate Events

Executive/Board ChangesShareholder Meetings
Voyager Therapeutics Approves Stock Plans at Annual Meeting
Neutral
Jun 5, 2025

At the annual meeting held on June 3, 2025, Voyager Therapeutics‘ stockholders approved the 2025 Stock Incentive Plan and the Amended and Restated 2015 Employee Stock Purchase Plan, both previously adopted by the Board of Directors. Additionally, stockholders elected four Class I directors to serve until the 2028 meeting, approved executive compensation, and ratified Ernst & Young LLP as the independent accounting firm for the fiscal year ending December 31, 2025. These decisions are expected to impact the company’s governance and operational strategies moving forward.

The most recent analyst rating on (VYGR) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 08, 2025